High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)-Reference-Cited by-同舟云学术

High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)

Published:2011-09-13 Issue:3 Volume:53 Page:445-450
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Larson Sarah M.,Campbell Nicholas P.,Huo Dezheng,Artz Andrew,Zhang Yanming,Gajria Devika,Green Margaret,Weiner Howie,Daugherty Christopher,Odenike Olatoyosi,Godley Lucy A.,Hyjek Elizabeth,Gurbuxani Sandeep,Thirman Michael,Sipkins Dorothy,van Besien Koen,Larson Richard A.,Stock Wendy

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.621562

Reference41 articles.

1. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem

2. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

3. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

4. Poor prognosis acute myelogenous leukemia: 1 – response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine)

5. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating targeted therapies in older patients with TP53 -mutated AML;Leukemia & Lymphoma;2024-04-22

2. Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy;Advanced Science;2023-06-04

3. Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future;Acta Haematologica;2023

4. The Applications of Mitoxantrone and Its Liposome in Adult Acute Myeloid Leukemia;Open Journal of Blood Diseases;2023

5. Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement;Blood Advances;2020-10-13